DISC-3405

Monoclonal antibody

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Sickle Cell Disease · Phase 1

Company guidance: data expected fourth quarter of 2026 (Disc Medicine, 5 Nov 2026). “We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Polycythemia Vera
Phase 1 (2)
Sickle Cell Disease
Other / comorbidity
NCT06050915 · Disc Medicine, Inc
2023-10-03 – 2024-07-09 · Healthy Volunteer
What this study did

Competitive landscape

This drug's own stage for Polycythemia Vera: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
DISC-3405: this drugPhase 2Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
Ropeginterferon Alfa-2b (Besremi)ApprovedProtein / enzyme therapeuticType I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
RusfertideApprovedPeptideFerroportinReliable signal
NCT05210790: Response in weeks 20 to 32 (Part 1a): rusfertide 76.9% (n=147) vs placebo 32.9% (n=146), odds ratio 6.42 (95% CI 3.81 to 10.80), p<0.0001 (CT.gov posted results).
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT01243944: The Percentage of Participants Achieving a Primary Response at Week 32 (32 Weeks): Ruxolitinib 22.7 percentage of participants (95% CI 15.3 to 31.7) | Best Available Therapy 0.9 percentage of participants (95% CI 0 to 4.9)
GivinostatPhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow DISC-3405 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 1Sickle Cell DiseaseRecruiting
Est. primary completion 2027-06 · NCT07187973 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Polycythemia VeraActive not recruiting
Est. primary completion 2027-07 · NCT06985147 · CT.gov ↗
What to watch

See the full readout calendar ↗